和元生物技术（上海）股份有限公司2026年第一次临时股东会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on February 26, 2026, in Shanghai, with all board members present and the meeting conducted in accordance with legal regulations [2][3][4] - Two resolutions were passed during the meeting: one regarding the establishment of an industrial merger fund and related transactions, and another concerning the change of the company's name and amendments to the articles of association [4][5] - The resolutions received the necessary majority votes, with the second resolution requiring a two-thirds majority and the first resolution requiring a simple majority [5][6] Group 2 - The company reported its preliminary financial data for the year 2025, indicating a revenue of 267.66 million yuan, a year-on-year increase of 7.86%, and a net loss attributable to shareholders of 220.72 million yuan, a reduction in loss by 10.11 million yuan compared to the previous year [9][12] - The total assets at the end of the reporting period were 2.10 billion yuan, a decrease of 7.89%, while the equity attributable to shareholders decreased by 18.24% to 1.42 billion yuan [12][13] - The company focused on its core business in cell and gene therapy, leveraging national and industry development policies to strategically position itself in the regenerative medicine sector, while also enhancing customer resource reserves and brand influence [12][13]